Boston Medical Group

Premature ejaculation (PE) is among the most common male sexual dysfunctions, affecting between 20% and 30% of sexually active men worldwide. Characterized by an inability to delay orgasm during intercourse, PE can disrupt relationships, lower self-confidence, and contribute to performance anxiety and even erectile dysfunction (ED). In the search for new and effective treatments, attention […]

Premature ejaculation (PE) is one of the most common yet misunderstood male sexual disorders, affecting men of all ages and often causing significant emotional distress and relationship difficulties. While nearly every man may occasionally ejaculate sooner than desired, true premature ejaculation involves consistently unwanted fast ejaculation, typically defined as under one minute of intravaginal ejaculatory […]

Every year, the treatment landscape for men facing erectile dysfunction (ED) and hypoactive sexual desire disorder (HSDD) is evolving beyond traditional options, giving hope to more and more men. One of the most promising solutions is PT-141, a melanocortin-based peptide therapy known for its ability to activate sexual desire through the central nervous system rather […]

PT-141, commonly known as Bremelanotide, is a groundbreaking peptide hormone analog used to treat sexual dysfunction in both men and women. Initially derived from the melanocortin analog Melanotan II, PT-141 works by targeting melanocortin receptors in the central nervous system, specifically the brain’s hypothalamus and arcuate nucleus. Unlike traditional treatments like Viagra that act on […]

Erectile dysfunction (ED) is a widespread condition affecting millions of men, often resulting from a wide range of underlying issues such as diabetes, cardiovascular disease, psychological stress, or prostate surgery. While first-line treatments like oral sildenafil citrate (Viagra), tadalafil (Cialis), and other PDE5 inhibitors are effective for many, they don’t work for everyone. For men […]